Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Cancer stem cells as targets for cancer therapy: selected cancers as examples
Department Human Anatomy and Cell Science, University of Manitoba, Winnipeg, Canada .
Manitoba Institute of Cell Biology, CancerCare Manitoba, Winnipeg, Canada .
Department of Human Genetics, University of Aarhus, Aarhus, Denmark.
Department of Animal Science, Faculty of Veterinary Medicine, University of Milan, Milan, Italy .
Show others and affiliations
2008 (English)In: Archivum Immunologiae et Therapiae Experimentalis, ISSN 0004-069X, E-ISSN 1661-4917, Vol. 56, no 3, 165-180 p.Article, review/survey (Refereed) Published
Abstract [en]

It is becoming increasingly evident that cancer constitutes a group of diseases involving altered stem-cell maturation/differentiation and the disturbance of regenerative processes. The observed malignant transformation is merely a symptom of normal differentiation processes gone astray rather than the primary event. This review focuses on the role of cancer stem cells (CSCs) in three common but also relatively under-investigated cancers: head and neck, ovarian, and testicular cancer. For didactic purpose, the physiology of stem cells is first introduced using hematopoietic and mesenchymal stem cells as examples. This is followed by a discussion of the (possible) role of CSCs in head and neck, ovarian, and testicular cancer. Aside from basic information about the pathophysiology of these cancers, current research results focused on the discovery of molecular markers specific to these cancers are also discussed. The last part of the review is largely dedicated to signaling pathways active within various normal and CSC types (e.g. Nanog, Nestin, Notch1, Notch2, Oct3 and 4, Wnt). Different elements of these pathways are also discussed in the context of therapeutic opportunities for the development of targeted therapies aimed at CSCs. Finally, alternative targeted anticancer therapies arising from recently identified molecules with cancer-(semi-)selective capabilities (e.g. apoptin, Brevinin-2R) are considered.

Place, publisher, year, edition, pages
2008. Vol. 56, no 3, 165-180 p.
National Category
Cancer and Oncology Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy) Cell Biology
Identifiers
URN: urn:nbn:se:liu:diva-86925DOI: 10.1007/s00005-008-0023-4ISI: 000256927300003OAI: oai:DiVA.org:liu-86925DiVA: diva2:583299
Available from: 2013-01-07 Created: 2013-01-07 Last updated: 2017-12-06

Open Access in DiVA

fulltext(628 kB)